Cosmo Bio Co

Cosmo Bio Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cosmo Bio Co (3386.T) as of Oct 27, 2026 is 342.00 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 318.00 M JPY — a change of 7.55% (higher).

EBITDA

342.00 MJPY

YoY

7.55%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cosmo Bio Co is 2025 342.00 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cosmo Bio Co was 2024 318.00 M JPY. It decreases by 7.55% higher compared to the previous year.

The Cosmo Bio Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
329.00 M JPY
Jan 1, 2019
406.00 M JPY
Jan 1, 2020
752.00 M JPY
Jan 1, 2021
1.05 B JPY
Jan 1, 2022
816.00 M JPY
Jan 1, 2023
519.00 M JPY
Jan 1, 2024
318.00 M JPY
Jan 1, 2025
342.00 M JPY
The Cosmo Bio Co EBITDA history
YEAREBITDAYoY
342.00 MJPY+7.55%
318.00 MJPY-38.73%
519.00 MJPY-36.40%
816.00 MJPY-22.14%
1.05 BJPY+39.36%
752.00 MJPY+85.22%
406.00 MJPY+23.40%
329.00 MJPY+69.59%
194.00 MJPY-55.71%
438.00 MJPY+117.91%
201.00 MJPY+23.31%
163.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cosmo Bio Co is 342.00 M JPY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cosmo Bio Co changed from 318.00 M JPY to 342.00 M JPY, representing a 7.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co